- Home
- IMVT vs LMT Comparison
IMVT vs LMT Comparison
Compare IMVT & LMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- LMT
- Stock Information
- Founded
- IMVT N/A
- LMT 1912
- Country
- IMVT United States
- LMT United States
- Employees
- IMVT N/A
- LMT N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- LMT Military/Government/Technical
- Sector
- IMVT Health Care
- LMT Industrials
- Exchange
- IMVT Nasdaq
- LMT Nasdaq
- Market Cap
- IMVT 3.6B
- LMT 121.6B
- IPO Year
- IMVT N/A
- LMT N/A
- Fundamental
- Price
- IMVT $25.19
- LMT $482.68
- Analyst Decision
- IMVT Strong Buy
- LMT Buy
- Analyst Count
- IMVT 10
- LMT 11
- Target Price
- IMVT $47.22
- LMT $615.27
- AVG Volume (30 Days)
- IMVT 945.7K
- LMT 1.2M
- Earning Date
- IMVT 02-10-2025
- LMT 01-28-2025
- Dividend Yield
- IMVT N/A
- LMT 2.73%
- EPS Growth
- IMVT N/A
- LMT 0.98
- EPS
- IMVT N/A
- LMT 27.67
- Revenue
- IMVT N/A
- LMT $71,295,000,000.00
- Revenue This Year
- IMVT N/A
- LMT $6.49
- Revenue Next Year
- IMVT N/A
- LMT $3.91
- P/E Ratio
- IMVT N/A
- LMT $17.45
- Revenue Growth
- IMVT N/A
- LMT 5.33
- 52 Week Low
- IMVT $23.88
- LMT $413.92
- 52 Week High
- IMVT $45.58
- LMT $618.95
- Technical
- Relative Strength Index (RSI)
- IMVT 40.99
- LMT 30.61
- Support Level
- IMVT $23.88
- LMT $481.85
- Resistance Level
- IMVT $26.46
- LMT $493.47
- Average True Range (ATR)
- IMVT 1.19
- LMT 7.04
- MACD
- IMVT -0.19
- LMT 1.24
- Stochastic Oscillator
- IMVT 25.10
- LMT 22.57
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
About LMT Lockheed Martin Corporation
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Lockheed's largest segment is aeronautics, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.